5.12
Schlusskurs vom Vortag:
$5.56
Offen:
$5.41
24-Stunden-Volumen:
4.93M
Relative Volume:
2.77
Marktkapitalisierung:
$545.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-258.08M
KGV:
-1.8618
EPS:
-2.75
Netto-Cashflow:
$-202.32M
1W Leistung:
-32.54%
1M Leistung:
-40.88%
6M Leistung:
-68.80%
1J Leistung:
-79.50%
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Firmenname
Rocket Pharmaceuticals Inc
Sektor
Branche
Telefon
646-440-9100
Adresse
350 FIFTH AVENUE, NEW YORK, NY
Vergleichen Sie RCKT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RCKT
Rocket Pharmaceuticals Inc
|
5.12 | 545.94M | 0 | -258.08M | -202.32M | -2.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
2024-12-30 | Eingeleitet | Wedbush | Outperform |
2024-12-18 | Eingeleitet | Jefferies | Buy |
2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
2024-04-02 | Eingeleitet | Goldman | Neutral |
2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-02-01 | Eingeleitet | Morgan Stanley | Overweight |
2022-11-08 | Eingeleitet | Canaccord Genuity | Buy |
2022-11-01 | Eingeleitet | BTIG Research | Buy |
2022-07-08 | Eingeleitet | Raymond James | Outperform |
2021-10-20 | Fortgesetzt | Cowen | Outperform |
2021-03-02 | Eingeleitet | Stifel | Buy |
2021-02-18 | Eingeleitet | Needham | Buy |
2020-12-16 | Eingeleitet | UBS | Buy |
2020-12-08 | Herabstufung | Oppenheimer | Outperform → Perform |
2020-07-02 | Eingeleitet | JP Morgan | Overweight |
2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
2019-11-06 | Eingeleitet | Chardan Capital Markets | Buy |
2019-09-26 | Eingeleitet | Piper Jaffray | Overweight |
2019-04-23 | Eingeleitet | Robert W. Baird | Outperform |
2019-03-15 | Eingeleitet | BofA/Merrill | Buy |
2019-02-05 | Eingeleitet | Oppenheimer | Outperform |
2018-09-13 | Eingeleitet | Ladenburg Thalmann | Buy |
2018-07-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Thrivent Financial for Lutherans Sells 21,731 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? - MSN
Where are the Opportunities in (RCKT) - news.stocktradersdaily.com
Teacher Retirement System of Texas Raises Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 1-Year LowHere's Why - MarketBeat
Swiss National Bank Has $1.93 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals’ SWOT analysis: gene therapy stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals’ SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India
Cantor Fitzgerald maintains Overweight on Rocket Pharmaceuticals stock By Investing.com - Investing.com Canada
Charles Schwab Investment Management Inc. Has $8.25 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Cantor Fitzgerald maintains Overweight on Rocket Pharmaceuticals stock - Investing.com India
(RCKT) Technical Pivots with Risk Controls - news.stocktradersdaily.com
PNC Financial Services Group Inc. Increases Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Bank of New York Mellon Corp Buys 9,949 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Fanconi Anemia Pipeline 2025: FDA Approvals and Clinical Trials - openPR.com
What technical indicators reveal about RCKT stock - US Post News
Steward Partners Investment Advisory LLC Has $84,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by Arizona State Retirement System - Defense World
BMO Capital Markets Begins Coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
(RCKT) Investment Analysis and Advice - news.stocktradersdaily.com
BMO Capital Initiates Coverage on Rocket Pharmaceuticals With Outperform Rating, $50 Price Target - Marketscreener.com
BMO Capital Initiates Coverage of Rocket Pharmaceuticals (RCKT) with Outperform Recommendation - Nasdaq
Rocket Pharmaceuticals: A Buy Rating for Its Pioneering Gene Therapy Approach and Promising Pipeline - TipRanks
BMO Capital sets $50 target for Rocket Pharmaceuticals stock - Investing.com India
BMO Capital sets $50 target for Rocket Pharmaceuticals stock By Investing.com - Investing.com Canada
Private Advisor Group LLC Acquires Shares of 13,199 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by New York State Common Retirement Fund - Defense World
Rhumbline Advisers Has $1.25 Million Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Research Analysts Set Expectations for RCKT FY2025 Earnings - Defense World
Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory - Insider Monkey
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Handelsbanken Fonder AB Has $290,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $15.00 by Analysts at The Goldman Sachs Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Raised to $52.00 at Scotiabank - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $36.00 at Canaccord Genuity Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 1-Year Low on Analyst Downgrade - Defense World
Rocket Pharmaceuticals Inc (NASDAQ: RCKT)’s Stock Adds 0.53%, Making It A Good Investment - Stocks Register
Scotiabank raises Rocket Pharmaceuticals target to $52 - Investing.com
What is William Blair’s Estimate for RCKT Q1 Earnings? - Defense World
What is Leerink Partnrs’ Estimate for RCKT Q2 Earnings? - Defense World
Chardan Capital Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $54.00 - Defense World
Needham & Company LLC Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $42.00 - Defense World
Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs - MSN
When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit? - Yahoo Finance Australia
Decoding Rocket Pharmaceuticals Inc (RCKT): A Strategic SWOT Ins - GuruFocus
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus - MSN
Rocket Pharmaceuticals Advances Gene Therapy Pipeline - TipRanks
Rocket Pharmaceuticals (NASDAQ:RCKT) Posts Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 12-Month LowHere's What Happened - MarketBeat
Finanzdaten der Rocket Pharmaceuticals Inc-Aktie (RCKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rocket Pharmaceuticals Inc-Aktie (RCKT) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Schwartz Jonathan David | See Remarks |
May 17 '24 |
Sale |
23.35 |
2,754 |
64,306 |
169,659 |
Schwartz Jonathan David | See Remarks |
Aug 16 '24 |
Sale |
18.50 |
2,710 |
50,135 |
166,949 |
Schwartz Jonathan David | See Remarks |
Nov 21 '24 |
Sale |
13.05 |
3,097 |
40,416 |
163,852 |
Patel Kinnari | See Remarks |
Feb 21 '25 |
Sale |
10.58 |
6,078 |
64,305 |
444,103 |
Wilson Martin | General Counsel |
Feb 21 '25 |
Sale |
10.58 |
3,222 |
34,089 |
150,696 |
Militello John | See Remarks |
Feb 21 '25 |
Sale |
10.58 |
2,737 |
28,957 |
65,757 |
Shah Gaurav | CEO |
Feb 21 '25 |
Sale |
10.58 |
16,303 |
172,486 |
772,680 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):